Skip to main content

Table 3 Treatment after the second-line chemotherapy

From: Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Treatment BBP group (%) Non-BBP group (%)
 No 16 (43.2) 17 (68.0)
 Yes (overlapping) 21 (56.8) 8 (32.0)
  TAS-102 15 (40.5) 6 (26.1)
  REGO 14 (37.8) 13 (50.0)
  CET/PANI 3 (8.1) 2 (8.7)
  Oxaliplatin-based 2 (5.4) 2 (8.7)
  Irinotecan-based 17 (45.9) 8 (34.8)
  Hepatic arterial infusion 4 (10.8) 4 (11.1)
  Others 4 (10.8) 4 (16.0)
  1. Abbreviations: BBP Bevacizumab continuation beyond progression, REGO Regorafenib, CET Cetuximab, PANI Panitumumab